Physioneal 35 Glucose 3.86% w/v / 38.6 mg/ml Clear-Flex,Solution for peritoneal dialysis Ireland - English - HPRA (Health Products Regulatory Authority)

physioneal 35 glucose 3.86% w/v / 38.6 mg/ml clear-flex,solution for peritoneal dialysis

baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 3.86 percent weight/volume - hypertonic solutions

Physioneal 40 Glucose 1.36% w/v / 13.6 mg/ml Clear-Flex,Solution for peritoneal dialysis Ireland - English - HPRA (Health Products Regulatory Authority)

physioneal 40 glucose 1.36% w/v / 13.6 mg/ml clear-flex,solution for peritoneal dialysis

baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 1.36 percent weight/volume - hypertonic solutions

Physioneal 40 Glucose 2.27% w/v / 22.7 mg/ml Clear-Flex,Solution for peritoneal dialysis Ireland - English - HPRA (Health Products Regulatory Authority)

physioneal 40 glucose 2.27% w/v / 22.7 mg/ml clear-flex,solution for peritoneal dialysis

baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 2.27 percent weight/volume - hypertonic solutions

Physioneal 40 Glucose 3.86% w/v / 38.6 mg/ml Clear-Flex,Solution for peritoneal dialysis Ireland - English - HPRA (Health Products Regulatory Authority)

physioneal 40 glucose 3.86% w/v / 38.6 mg/ml clear-flex,solution for peritoneal dialysis

baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 3.86 percent weight/volume - hypertonic solutions

TOBRA-DAY tobramycin (as sulfate) 500mg/5 mL Injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

tobra-day tobramycin (as sulfate) 500mg/5 ml injection vial

phebra pty ltd - tobramycin sulfate, quantity: 762.24 mg (equivalent: tobramycin, qty 500 mg) - injection, concentrated - excipient ingredients: sulfuric acid; water for injections; sodium hydroxide - tobra-day is indicated for once daily intravenous use in the treatment of cystic fibrosis patients (greater than 5 years old) with acute pulmonary exacerbations caused by susceptible organisms.

TOBRAMYCIN VIATRIS tobramycin 80 mg/2 mL injection, solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

tobramycin viatris tobramycin 80 mg/2 ml injection, solution vial

alphapharm pty ltd - tobramycin, quantity: 40 mg/ml - injection, solution - excipient ingredients: sulfuric acid; sodium hydroxide; water for injections; disodium edetate; sodium bisulfite - tobramycin is indicated in the treatment of the following serious infections caused by susceptible micro-organisms: - central nervous system infections, including meningitis; septicaemia and neonatal sepsis; gastro-intestinal infections, including peritonitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis; bone, skin and skin structure infections, including burns.,tobramycin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgement indicate its use. aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes or urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.,bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to tobramycin. if susceptibility tests show that the causative organism is resistant to tobramycin, other appropriate therapy should be instituted. in patients in whom gram negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, severity of the infection, and the important additional concepts discussed under precautions.

Micro Gentamicin Injection 20mg/2ml Namibia - English - Namibia Medicines Regulatory Council

micro gentamicin injection 20mg/2ml

pharma - q holdings (pty) ltd - gentamycin sulphate - injection - each 2,0 ml ampoule contains gentamycin sulphate equiv. to gentamycin base 20,0 mg

Micro Gentamicin Injection 40mg/1ml Namibia - English - Namibia Medicines Regulatory Council

micro gentamicin injection 40mg/1ml

pharma - q holdings (pty) ltd - gentamycin sulphate - injection - each 1,0 ml ampoule contains gentamycin sulphate equiv. to gentamycin base 40,0 mg

Micro Gentamicin Injection 80mg/1ml Namibia - English - Namibia Medicines Regulatory Council

micro gentamicin injection 80mg/1ml

pharma - q holdings (pty) ltd - gentamycin sulphate - injection - each 2,0 ml ampoule contains gentamycin sulphate equiv. to gentamycin base 80,0 mg

Hitagen-100 g/L Sterile Solution For Injection Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hitagen-100 g/l sterile solution for injection

n.a.m. trading (ipoh) sdn bhd - gentamycin sulphate -